

Guldane Cengiz Seval

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2123311/publications.pdf>

Version: 2024-02-01

115
papers

4,551
citations

218677

26
h-index

110387

64
g-index

118
all docs

118
docs citations

118
times ranked

4556
citing authors

#	ARTICLE	IF	CITATIONS
1	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 754-766.	27.0	1,246
2	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 2096-2107.	13.7	435
3	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. <i>Haematologica</i> , 2015, 100, 1254-1266.	3.5	289
4	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. <i>New England Journal of Medicine</i> , 2021, 385, 46-58.	27.0	268
5	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	17.0	189
6	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 393, 253-264.	13.7	187
7	Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2021, 22, 801-812.	10.7	162
8	Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. <i>Blood</i> , 2020, 136, 3033-3040.	1.4	146
9	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology, The</i> , 2021, 22, e105-e118.	10.7	136
10	Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. <i>European Journal of Haematology</i> , 2011, 86, 16-22.	2.2	133
11	SARS-CoV-2 Mutations and their Viral Variants. <i>Cytokine and Growth Factor Reviews</i> , 2022, 63, 10-22.	7.2	113
12	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2021, 35, 31-44.	7.2	79
13	HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA. <i>Journal of Hematology and Oncology</i> , 2021, 14, 54.	17.0	75
14	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018, 32, 1542-1560.	7.2	68
15	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	2.5	67
16	The safety of bortezomib for the treatment of multiple myeloma. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 953-962.	2.4	64
17	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e401-e419.	0.4	61
18	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 4030-4041.	1.6	56

#	ARTICLE	IF	CITATIONS
19	Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). <i>Leukemia</i> , 2020, 34, 1840-1852.	7.2	55
20	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 416-427.	10.7	54
21	A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. <i>Haematologica</i> , 2020, 105, 201-208.	3.5	48
22	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , the, 2021, 8, e934-e946.	4.6	46
23	Phase 2 study of tabalumab, a human anti- β 2-microglobulin activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. <i>British Journal of Haematology</i> , 2017, 176, 783-795.	2.5	39
24	An artificial intelligent diagnostic system on differential recognition of hematopoietic cells from microscopic images. , 1997, 30, 145-150.		37
25	Blood donors and factors impacting the blood donation decision: Motives for donating blood in Turkish sample. <i>Transfusion and Apheresis Science</i> , 2013, 49, 468-473.	1.0	37
26	CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma. <i>Molecular Cancer</i> , 2021, 20, 84.	19.2	33
27	Stem Cell Therapy in Spinal Cord Injury: In Vivo and Postmortem Tracking of Bone Marrow Mononuclear or Mesenchymal Stem Cells. <i>Stem Cell Reviews and Reports</i> , 2012, 8, 953-962.	5.6	30
28	A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 563-571.	2.4	25
29	Isatuximab for the treatment of relapsed/refractory multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1395-1404.	3.1	22
30	Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2018, 97, 1027-1039.	1.8	19
31	Impact of α -Killer Immunoglobulin-Like Receptor /Ligand Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival. <i>PLoS ONE</i> , 2015, 10, e0132526.	2.5	19
32	Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients. <i>Journal of Clinical Medicine</i> , 2015, 4, 441-459.	2.4	17
33	Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma. <i>Frontiers in Oncology</i> , 2020, 10, 767.	2.8	16
34	Tandem Autologous (ASCT)/ Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with Identical Sibling Donor Versus ASCT in Previously Untreated Multiple Myeloma (MM): Long Term Follow up of a Prospective Controlled Trial by the EBMT.. <i>Blood</i> , 2009, 114, 52-52.	1.4	15
35	Efficacy and safety of weekly carfilzomib (70 mg/m ²), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. <i>Leukemia and Lymphoma</i> , 2021, 62, 358-367.	1.3	13
36	Suppression of steroid 5 α -reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma. <i>Cell Death and Disease</i> , 2021, 12, 206.	6.3	13

#	ARTICLE	IF	CITATIONS
37	Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study. <i>British Journal of Haematology</i> , 2017, 178, 61-71.	2.5	12
38	Drug Targeting of Genomic Instability in Multiple Myeloma. <i>Frontiers in Genetics</i> , 2020, 11, 228.	2.3	12
39	A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65-75 Yrs Enrolled in MM-015. <i>Blood</i> , 2011, 118, 475-475.	1.4	12
40	Current Approach to Non-Infectious Pulmonary Complications of Hematopoietic Stem Cell Transplantation. <i>Balkan Medical Journal</i> , 2018, 35, 131-140.	0.8	12
41	Role of Killer Immunoglobulin-Like Receptor and Ligand Matching in Donor Selection. <i>Bone Marrow Research</i> , 2012, 2012, 1-6.	1.7	11
42	Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 163-171.	1.3	11
43	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 284-293.	1.2	11
44	Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group. <i>Journal of Clinical Medicine</i> , 2021, 10, 3940.	2.4	10
45	Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM). <i>Blood</i> , 2018, 132, 1994-1994.	1.4	10
46	Circulating CD44 and intercellular adhesion molecule-1 levels in low grade non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia patients during interferon- α 2a treatment. <i>Cancer</i> , 2000, 89, 1474-1481.	4.1	9
47	PET with Fluorodeoxyglucose F 18/Computed Tomography as a Staging Tool in Multiple Myeloma. <i>PET Clinics</i> , 2019, 14, 369-381.	3.0	9
48	Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial. <i>Blood</i> , 2018, 132, 301-301.	1.4	9
49	A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis. <i>Leukemia and Lymphoma</i> , 2019, 60, 151-162.	1.3	8
50	Blastic Plasmacytoid Dendritic Cell Neoplasm: Single Center Experience on a Rare Hematological Malignancy. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2021, 37, 67-75.	0.6	8
51	COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey. <i>Blood Advances</i> , 2022, 6, 3870-3874.	5.2	8
52	Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia. <i>Medical Oncology</i> , 1998, 15, 183-190.	2.5	7
53	Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e474-e484.	0.4	7
54	Impact of COVID-19 pandemic on global unrelated stem cell donations in 2020—Report from World Marrow Donor Association. <i>Bone Marrow Transplantation</i> , 2022, 57, 1021-1024.	2.4	7

#	ARTICLE	IF	CITATIONS
55	A model integrating Killer Immunoglobulin-like Receptor (KIR) haplotypes for risk prediction of COVID-19 clinical disease severity. <i>Immunogenetics</i> , 2021, 73, 449-458.	2.4	5
56	Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1793-1804.	1.8	4
57	Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95). <i>Blood</i> , 2020, 136, 46-48.	1.4	4
58	Determination of the Apoptotic Effect and Molecular Docking of Benzamide Derivative XT5 in K562 Cells. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 18, 1521-1530.	1.7	4
59	Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report. <i>Turkish Journal of Haematology</i> , 2015, 32, 180-183.	0.5	4
60	Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model. <i>Turkish Journal of Haematology</i> , 2017, 34, 137-142.	0.5	4
61	The natural course of non-alcoholic fatty liver disease. <i>Hepatology Forum</i> , 2020, , 20-24.	0.5	4
62	Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation. <i>Turkish Journal of Gastroenterology</i> , 2019, 30, 122-131.	1.1	3
63	Fetal Cell Microchimerism; Normal and Immunocompromised Gestations in Mice. <i>Fetal and Pediatric Pathology</i> , 2020, 39, 277-287.	0.7	3
64	Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial. <i>Blood</i> , 2018, 132, 3186-3186.	1.4	3
65	Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study. <i>Blood</i> , 2020, 136, 4-6.	1.4	3
66	Is Quantification of Measurable Clonal Plasma Cells in Stem Cell Grafts (gMRD) Clinically Meaningful?. <i>Frontiers in Oncology</i> , 2022, 12, 800711.	2.8	3
67	Host variations in SARS-CoV-2 infection. <i>Turkish Journal of Biology</i> , 2021, 45, 404-424.	0.8	2
68	Preliminary Results Of A Mass Spectrometry Based Bottom Up Proteomic Approach On Bone Marrow Plasma Cells From Patients With Multiple Myeloma (MM). <i>Blood</i> , 2013, 122, 1887-1887.	1.4	2
69	Natural Killer Cell-Mediated Cellular Therapy of Hematological Malignancies. <i>Clinical Hematology International</i> , 2019, 1, 134-141.	1.7	2
70	When a Monoclonal Gammopathy Is Not Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 655-664.	3.8	2
71	Flowcytometric evaluation of cell cycle regulators (cyclins and cyclin dependent kinase inhibitors) expressed on bone marrow cells of patients with chronic myelogenous leukemia and multiple myeloma. <i>Turkish Journal of Haematology</i> , 2012, 29, 17-27.	0.5	1
72	Comparing Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S306.	0.4	1

#	ARTICLE	IF	CITATIONS
73	Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable Δ VR Responses Among Immunomodulatory / Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e242-e243.	0.4	1
74	Prognostic scoring system after transplantation in myeloma: predicting early relapse. <i>British Journal of Haematology</i> , 2020, 191, 323-324.	2.5	1
75	Ibrutinib As a Promising Treatment for Pulmonary Complications Due to Refractory Chronic Graft Versus Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S191.	2.0	1
76	A Rare Extramedullary Presentation of Multiple Myeloma: Paraspinal Muscle Involvement Revealed by FDG PET/CT. <i>Turkish Journal of Haematology</i> , 2021, 38, 69-71.	0.5	1
77	Pleural Involvement Upon Relapse of Myeloma Responding to Daratumumab Plus Carfilzomib: A Case Presentation and Literature Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e267-e271.	0.4	1
78	Circulating CD44 and intercellular adhesion molecule-1 levels in low grade non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia patients during interferon- α treatment. <i>Cancer</i> , 2000, 89, 1474-1481.	4.1	1
79	Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice. <i>Blood</i> , 2015, 126, 3034-3034.	1.4	1
80	Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study. <i>Blood</i> , 2021, 138, 2747-2747.	1.4	1
81	Editorial: "How to Improve Cord Blood Transplantation: By Enhancing Cell Counts or Engraftment?". <i>Frontiers in Medicine</i> , 2016, 3, 20.	2.6	0
82	Age is Not an Important Factor for Autologous Peripheral Hematopoietic Stem Cell Mobilization and Collection in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S142.	2.0	0
83	Negative Impact of High LDH at Diagnosis on OS, But Not PFS, Can Be Overcome by Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e197.	0.4	0
84	KIR Genotype and KIR Ligand Phenotypes That Improve the in Vitro Cord Blood or Autologous NK Cell Mediated Cytotoxicity Against Myeloma Marrow Plasma Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S315.	2.0	0
85	Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S305-S306.	2.0	0
86	Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S109-S110.	2.0	0
87	Rosai-Dorfman disease presenting with nasal, nodal and multiple cutaneous involvements responding to a combination of systemic steroid and low-dose thalidomide therapy. <i>Dermatologic Therapy</i> , 2021, 34, e14988.	1.7	0
88	Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors. <i>Turkish Journal of Haematology</i> , 2021, 38, 111-118.	0.5	0
89	Hematopoietic Stem Cell Transplantation for Patients with Paroxysmal Nocturnal Hemoglobinuria with or Without Aplastic Anemia: Multicenter Turkish Experience. <i>Turkish Journal of Haematology</i> , 2021, 38, 195-203.	0.5	0
90	Brentuximab Vedotin Treatment in Relaps Refractory Hodgkin Lymphoma: A Single Center Experience. <i>LLM Dergi</i> , 2021, 5, 1-4.	0.0	0

#	ARTICLE	IF	CITATIONS
91	Allogeneic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: A Single Center Experience. LLM Dergi, 2021, 5, 16-20.	0.0	0
92	The Influence of ATG on the Outcomes of Patients With AML at the Time of Unrelated Donor Transplantation. Journal of Ankara University Faculty of Medicine, 2021, 74, 337-342.	0.1	0
93	Treatment approaches for managing patients with hematological malignancies in the time of COVID-19 pandemic. Turkish Journal of Medical Sciences, 2021, , .	0.9	0
94	A New Predictive and Prognostic Marker for De Novo AML: Peripheral Blood CD34 (pCD34) Count at Recovery Following Remission Induction (RI) Therapy (Supp. by Ankara University-2003-0809114).. Blood, 2005, 106, 4517-4517.	1.4	0
95	The Impact of Methylenetetrahydrofolate Reductase C677T Gene Polymorphism on Engraftment after Allogeneic Hematopoietic Cell Transplantation.. Blood, 2005, 106, 5318-5318.	1.4	0
96	Pyrimidine 5â€² Nucleotidase-1 (P5N-1) Deficiency Associated with 4 Novel Mutations in 5 New Turkish Families: Genotype-Phenotype Analysis.. Blood, 2006, 108, 3743-3743.	1.4	0
97	Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndrome: A Retrospective Validation From a Single Centre.. Blood, 2009, 114, 4846-4846.	1.4	0
98	Immunophenotyping Features in Acute Myeloid Leukemia (AML) with NPM1+ and/or FLT3+. Blood, 2011, 118, 4908-4908.	1.4	0
99	Comparison Of Flow Cytometric and Clinical Findings In Patients With Paroxysmal Nocturnal Hemoglobinuria. Blood, 2013, 122, 4877-4877.	1.4	0
100	ERRATUM. Methods in Molecular Biology, 2014, 1109, E1-E2.	0.9	0
101	Retrospective Analysis of 149 Unselected Patients with Mantle Cell Lymphoma Confirms Prognostic Relevance of Mantle Cell Lymphoma International Prognostic Index: Single Center Experience. Blood, 2018, 132, 5331-5331.	1.4	0
102	KIR 2DS4 May Influence Autologous and Cord Blood(CB) Natural Killer (NK)Cell Mediated in Vitro Cytotoxicity Against Freshly Isolated Human Bone Marrow Myeloma Plasma Cells and Cell Lines. Blood, 2018, 132, 1920-1920.	1.4	0
103	Residual Clonal Plasma Cells Detected By Flow Cytometry at 10 ⁻⁴ level within Autologous Stem Cell Grafts Is Associated with Significantly Less Overall Survival. Blood, 2018, 132, 3438-3438.	1.4	0
104	Is the End Close for the Graft-Versus-Host Disease That Is a Big Problem Following Allogeneic Hematopoietic Stem Cell Transplantation?. Blood, 2018, 132, 5729-5729.	1.4	0
105	Donor Lymphocyte Infusions for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. Blood, 2018, 132, 4673-4673.	1.4	0
106	Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?. Journal of Clinical Oncology, 2019, 37, e19524-e19524.	1.6	0
107	Impact of Hepatitis B Core Antibody Seropositivity on the Liver Function Tests After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. LLM Dergi, 2019, 3, 55-59.	0.0	0
108	Safety and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Mycosis Fungoides and Sezary Syndrome: A 7-year Tertiary Center Analysis. LLM Dergi, 2020, 4, 23-27.	0.0	0

#	ARTICLE	IF	CITATIONS
109	First Turkey Experience of 11C-Methionine PET in Multiple Myeloma. Turkish Journal of Haematology, 2020, , .	0.5	0
110	Relapse of Immune Thrombocytopenic Purpura in a Patient With COVID-19. Infectious Diseases and Clinical Microbiology, 2020, 2, 184-186.	0.3	0
111	The Outcomes of Splenectomy and Drug Therapy in Patients with Splenic Marginal Zone Lymphoma. LLM Dergi, 2020, 4, 10-13.	0.0	0
112	Results of an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma in Emerging Markets (INTEGRATE). Blood, 2021, 138, 3045-3045.	1.4	0
113	A Bottom-Up Proteomic Approach in Bone Marrow Plasma Cells of Newly Diagnosed Multiple Myeloma Patients. Current Proteomics, 2021, 18, 730-741.	0.3	0
114	Bir Nakil Merkezinin 11 YÄ±llÄ±k Allojeneik KÄ¶k HÄ¼cre Nakli Deneyimi. LLM Dergi, 2020, 4, 50-54.	0.0	0
115	The evolving treatment paradigm of multiple myeloma: From past to present and future. Turkish Journal of Haematology, 2008, 25, 60-70.	0.5	0